When the PAP was available, compared to the control strategy with a cost-effectiveness threshold of US $32,000, the proportions of simulations with cost-effectiveness for NGS panel testing and multiplex PCR testing followed by crizotinib treatment for ALK rearrangement-positive NSCLC were 82.3% and 82.9%, respectively. The gene discussed is ALK; the disease is non-small cell lung carcinoma.